
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule for nasal irrigation or nebulizer use containing mometasone furoate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing mometasone are listed in spray, ointment, cream, aerosol, solution and inhalant forms. No finished mometasone product of any kind is listed in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Prescribers order these capsules to be mixed into a saline sinus rinse for patients with chronic sinusitis or nasal polyps, often after sinus surgery. Manufactured mometasone is FDA-approved as a nasal spray for these conditions; adding it to a sinus rinse is off-label.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Mometasone furoate is a medium-potency topical corticosteroid that compounding pharmacies prepare as creams, ointments, lotions and solutions by prescription.
Mometasone furoate is a synthetic corticosteroid. Applied to the skin, it enters cells and switches on anti-inflammatory proteins, including lipocortins, which calm the redness, swelling and itch of inflamed skin and narrow small blood vessels. Among topical steroids it sits in the medium-potency range, and only about 0.4 percent of an applied dose reaches the bloodstream through intact skin. Manufactured mometasone furoate cream, ointment and lotion (originally Elocon, now generics) are FDA-approved for relief of the inflammatory and itchy manifestations of corticosteroid-responsive dermatoses in patients two years and older. A prescriber might order compounded mometasone for a vehicle not manufactured, a base free of a preservative or lanolin a patient reacts to, or a combination with another topical ingredient in a single preparation. Compounded preparations are not FDA-approved and require a prescription.
Mometasone is for the skin only; keep it out of the eyes and mouth, and do not use it if you have reacted to it before. Avoid the face, groin and skin folds unless directed, and do not cover treated skin with bandages, plastic or diapers, which drive more steroid into the body. Enough can be absorbed, especially in children or over large areas, to suppress the adrenal glands, raise blood sugar or cause Cushing's syndrome. Topical steroids have been linked to cataracts and glaucoma; report any vision change. Common local effects are burning, itching, thinning skin, stretch marks and color change. Tell your prescriber about every steroid you use. Use in pregnancy only if clearly needed; LactMed considers short courses unlikely to harm a breastfed infant but says to keep the infant's skin away from treated areas. If side effects bother you, talk to your prescriber or pharmacist.
Mometasone furoate is a 17-heterocyclic corticosteroid with anti-inflammatory, antipruritic and vasoconstrictive activity; the label attributes the effect to induction of lipocortins that inhibit phospholipase A2. Percutaneous absorption is about 0.4 percent of the applied dose over eight hours on intact unoccluded skin and higher on inflamed skin or under occlusion. Potency is medium (groups IV to V in the AAFP classification). Labeled indication for mometasone furoate cream, ointment and lotion (generics; Elocon brand discontinued): inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, age two and older; the label limits pediatric use to three weeks and advises against diaper-area use. In a pediatric study of extensive application, adrenal suppression occurred in about 16 percent of subjects. No drug interaction studies have been conducted. Prescribers select the vehicle for the lesion type per AAFP guidance (ointments for dry hyperkeratotic plaques, creams for weeping or intertriginous skin, lotions for hairy areas); strength and duration are per prescriber. Monitoring: local atrophy, striae and telangiectasia, allergic contact dermatitis presenting as failure to heal, and HPA axis evaluation (cortisol or ACTH stimulation) when large areas, occlusion or prolonged use are involved. Tachyphylaxis can develop with continuous use. Not a controlled substance.
Wash your hands. Open one capsule and empty the powder into the volume of saline or water on your label, using only distilled, sterile, or boiled and cooled water if you are mixing it yourself. Stir or shake until dissolved. For a sinus rinse, lean over a sink and rinse each nostril with the device. For a nebulizer, pour the solution into the medicine cup and breathe normally through the mouthpiece or mask until the mist stops. Wash and air dry the rinse device or nebulizer cup after each use. Discard any mixed solution you do not use.
Keep the unopened capsules tightly closed in a dry place at room temperature and out of reach of children. The beyond-use date on your label depends on how the capsules were prepared and what they are for; the pharmacist sets it. Mix only one dose at a time and discard capsules after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Empty contents of 1 capsule and mix with saline solution and irrigate/nebulize